Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells

Clinical and Vaccine Immunology

Volumn 22, Issue 1, 2015, Pages 119-128

  Griffin, Amanda J ^a   Crane, Deborah D ^a   Wehrly, Tara D ^a   Bosio, Catharine M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TULAREMIA VACCINE; BACTERIAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CELL EXPANSION; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FRANCISELLA TULARENSIS; IMMUNITY; LUNG ALVEOLUS CELL; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; SPLEEN CELL; STRAIN DIFFERENCE; SURVIVAL; TULAREMIA; VACCINATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; SPLEEN; T LYMPHOCYTE;

ANIMALS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; FEMALE; FRANCISELLA TULARENSIS; MICE, INBRED C57BL; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TULAREMIA;

EID: 84920530769     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00648-14     Document Type: Article

References (43)

1. Ellis J, Oyston PC, Green M, Titball RW. 2002. Tularemia. Clin Microbiol Rev 15: 631-646. http://dx.doi.org/10.1128/CMR.15.4.631-646.2002.
2. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. 1961. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med 107: 702-714.
3. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K, Working Group on Civilian Biodefense. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285: 2763-2773. http://dx.doi.org/10.1001/jama.285.21.2763.
4. Sjostedt A. 2005. Francisella, p 200-210. In Brenner DJ, Krieg NR, Staley JT, Garrity GM (ed), Bergey's manual of systematic bacteriology, part B: the proteobacteria. Springer, New York, NY.
5. Eigelsbach HT, Tulis JJ, Overholt EL, Griffith WR. 1961. Aerogenic immunization of the monkey and guinea pig with live tularemia vaccine. Proc Soc Exp Biol Med 108: 732-734. http://dx.doi.org/10.3181/00379727-108-27049.
6. Eigelsbach HT, Downs CM. 1961. Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol 87: 415-425.
7. Parker RR, Spencer RR. 1926. Six additional cases of laboratory infection of tularemia in man. Public Health Rep 41: 1341-1357. http://dx.doi.org/10.2307/4577925.
8. McCrumb FR. 1961. Aerosol infection of man with Pasteurella tularensis. Bacteriol Rev 25: 262-267.
9. Anderson RV, Crane DD, Bosio CM. 2010. Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine 28: 6562-6572. http://dx.doi.org/10.1016/j.vaccine.2010.07.072.
10. Cowley SC, Elkins KL. 2011. Immunity to Francisella. Front Microbiol 2: 26. http://dx.doi.org/10.3389/fmicb.2011.00026.
11. Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR. 2005. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A. Infect Immun 73: 2644-2654. http://dx.doi.org/10.1128/IAI.73.5.2644-2654.2005.
12. Chen W, Shen H, Webb A, KuoLee R, Conlan JW. 2003. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background. Vaccine 21: 3690-3700. http://dx.doi.org/10.1016/S0264-410X(03)00386-4.
13. Bakshi CS, Malik M, Mahawar M, Kirimanjeswara GS, Hazlett KR, Palmer LE, Furie MB, Singh R, Melendez JA, Sellati TJ, Metzger DW. 2008. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine 26: 5276-5288. http://dx.doi.org/10.1016/j.vaccine.2008.07.051.
14. Bosio CM, Bielefeldt-Ohmann H, Belisle JT. 2007. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol 178: 4538-4547. http://dx.doi.org/10.4049/jimmunol.178.7.4538.
15. Chase JC, Bosio CM. 2010. The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun 78: 154-167. http://dx.doi.org/10.1128/IAI.00750-09.
16. Chase JC, Celli J, Bosio CM. 2009. Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun 77: 180-195. http://dx.doi.org/10.1128/IAI.00879-08.
17. Way SS, Thompson LJ, Lopes JE, Hajjar AM, Kollmann TR, Freitag NE, Wilson CB. 2004. Characterization of flagellin expression and its role in Listeria monocytogenes infection and immunity. Cell Microbiol 6: 235-242. http://dx.doi.org/10.1046/j.1462-5822.2004.00360.x.
18. Crane DD, Ireland R, Alinger JB, Small P, Bosio CM. 7 August 2013. Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via TLR2 and PPARalpha. Clin Vaccine Immunol http://dx.doi.org/10.1128/CVI.00319-13.
19. Griffin AJ, Crane DD, Wehrly TD, Scott DP, Bosio CM. 2013. Alternative activation of macrophages and induction of arginase are not components of pathogenesis mediated by Francisella species. PLoS One 8: e82096. http://dx.doi.org/10.1371/journal.pone.0082096.
20. Crane DD, Scott DP, Bosio CM. 2012. Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One 7: e33349. http://dx.doi.org/10.1371/journal.pone.0033349.
21. Crane DD, Griffin AJ, Wehrly TD, Bosio CM. 2013. B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses. J Immunol 190: 2756-2766. http://dx.doi.org/10.4049/jimmunol.1202697.
22. + thymocyte depletion. Microb Pathog 39: 189-196. http://dx.doi.org/10.1016/j.micpath.2005.08.005.
23. Wayne Conlan J, Shen H, Kuolee R, Zhao X, Chen W. 2005. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell-and interferon gamma-dependent mechanism. Vaccine 23: 2477-2485. http://dx.doi.org/10.1016/j.vaccine.2004.10.034.
24. Cowley SC, Myltseva SV, Nano FE. 1996. Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. Mol Microbiol 20: 867-874. http://dx.doi.org/10.1111/j.1365-2958.1996.tb02524.x.
25. Celli J, Zahrt TC. 2013. Mechanisms of Francisella tularensis intracellular pathogenesis. Cold Spring Harb Perspect Med 3: a010314. http://dx.doi.org/10.1101/cshperspect.a010314.
26. Faith NG, Kim JW, Azizoglu R, Kathariou S, Czuprynski C. 2012. Purine biosynthesis mutants (purA and purB) of serotype 4b Listeria monocytogenes are severely attenuated for systemic infection in intragas-trically inoculated A/J mice. Foodborne Pathog Dis 9: 480-486. http://dx.doi.org/10.1089/fpd.2011.1013.
27. Pechous RD, McCarthy TR, Mohapatra NP, Soni S, Penoske RM, Salzman NH, Frank DW, Gunn JS, Zahrt TC. 2008. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge. PLoS One 3: e2487. http://dx.doi.org/10.1371/journal.pone.0002487.
28. Pechous R, Celli J, Penoske R, Hayes SF, Frank DW, Zahrt TC. 2006. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain. Infect Immun 74: 4452-4461. http://dx.doi.org/10.1128/IAI.00666-06.
29. Thomas-Charles CA, Zheng H, Palmer LE, Mena P, Thanassi DG, Furie MB. 2013. FeoB-mediated uptake of iron by Francisella tularensis. Infect Immun 81: 2828-2837. http://dx.doi.org/10.1128/IAI.00170-13.
30. Horzempa J, O'Dee DM, Shanks RM, Nau GJ. 2010. Francisella tularensis DeltapyrF mutants show that replication in nonmacrophages is sufficient for pathogenesis in vivo. Infect Immun 78: 2607-2619. http://dx.doi.org/10.1128/IAI.00134-10.
31. Kadzhaev K, Zingmark C, Golovliov I, Bolanowski M, Shen H, Conlan W, Sjostedt A. 2009. Identification of genes contributing to the virulence of Francisella tularensis SCHU S4 in a mouse intradermal infection model. PLoS One 4: e5463. http://dx.doi.org/10.1371/journal.pone.0005463.
32. Twine S, Shen H, Harris G, Chen W, Sjostedt A, Ryden P, Conlan W. 2012. Balb/c mice, but not C57BL/6 mice immunized with a DeltaclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses. Vaccine 30: 3634-3645. http://dx.doi.org/10.1016/j.vaccine.2012.03.036.
33. Elkins KL, Cowley SC, Bosio CM. 2007. Innate and adaptive immunity to Francisella. Ann N Y Acad Sci 1105: 284-324. http://dx.doi.org/10.1196/annals.1409.014.
34. Elkins KL, Rhinehart-Jones TR, Culkin SJ, Yee D, Winegar RK. 1996. Minimal requirements for murine resistance to infection with Francisella tularensis LVS. Infect Immun 64: 3288-3293.
35. Melillo AA, Foreman O, Elkins KL. 2013. IL-12Rbeta2 is critical for survival of primary Francisella tularensis LVS infection. J Leukoc Biol 93: 657-667. http://dx.doi.org/10.1189/jlb.1012485.
36. +T cells to increase their abundance during virus infection. J Exp Med 201: 1053-1059. http://dx.doi.org/10.1084/jem.20041463.
37. + T cell responses. J Immunol 175: 5624-5628. http://dx.doi.org/10.4049/jimmunol.175.9.5624.
38. Traynor TR, Kuziel WA, Toews GB, Huffnagle GB. 2000. CCR2 expression determines T1 versus T2 polarization during pulmonary Cryptococcus neoformans infection. J Immunol 164: 2021-2027. http://dx.doi.org/10.4049/jimmunol.164.4.2021.
39. Traynor TR, Herring AC, Dorf ME, Kuziel WA, Toews GB, Huffnagle GB. 2002. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J Immunol 168: 4659-4666. http://dx.doi.org/10.4049/jimmunol.168.9.4659.
40. Jeong YH, Jeon BY, Gu SH, Cho SN, Shin SJ, Chang J, Ha SJ. 2014. Differentiation of antigen-specific T cells with limited functional capacity during Mycobacterium tuberculosis infection. Infect Immun 82: 132-139. http://dx.doi.org/10.1128/IAI.00480-13.
41. Cowley SC, Goldberg MF, Ho JA, Elkins KL. 2008. The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. J Infect Dis 198: 284-292. http://dx.doi.org/10.1086/589620.
42. Shen H, Chen W, Conlan JW. 2004. Susceptibility of various mouse strains to systemically-or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen. Vaccine 22: 2116-2121. http://dx.doi.org/10.1016/j.vaccine.2003.12.003.
43. KuoLee R, Harris G, Conlan JW, Chen W. 2007. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis. Vaccine 25: 3781-3791. http://dx.doi.org/10.1016/j.vaccine.2007.02.014.